NEW YORK – Paris-based biotech Transgene on Thursday said that the first head-and-neck cancer patient has been dosed with its individualized immunotherapy, TG4050, in a Phase I trial.
The cancer vaccine is personalized to each patient based on Transgene's Myvac viral vector-based immunotherapy platform and NEC's artificial intelligence-based Neoantigen Prediction System.
In the Phase I trial, up to 30 head-and-neck cancer patients will receive TG4050 in the UK, US, and France. Each patient will have their tumor tissue sequenced to identify mutations, a panel of mutations will be prioritized using NEC's Neoantigen Prediction System, and the Myvac platform will develop, manufacture, and deliver an immunotherapy specific to each patient. Half the patients will receive TG4050 right after adjuvant treatment, while the other half will receive it when their cancers recur.
In parallel, another Phase I study of TG4050 is enrolling ovarian cancer patients. The head-and-neck and ovarian cancer studies will report their first results in the second half of this year.